Novartis is a global healthcare company striving to reimagine medicine – driving the application of innovative science and technology in order to improve and prolong people’s lives. One of the largest pharmaceutical companies in the world, they are currently undergoing a period of digital transformation with the goal of streamlining operations, minimising costs and enhancing decision-making.
To achieve this, Novartis has launched initiatives across the business, equipping departments with the resources to develop digital solutions that transform their work processes.
Within the area of clinical trials, employees need to monitor emerging data in order to identify potential risks and determine suitable actions based on those insights. Failure to do so can jeopardise trials and potentially cost the business millions of dollars in wasted time and resource.
Employees were relying on outdated software to gather trial data from various sources, from which reports in specific areas of interest could be generated. The software was time-consuming and difficult to use, with users struggling to locate important information – hindering their ability to make accurate business decisions.
By providing employees with robust search capabilities and reliable data, we not only save time and improve accuracy, but also minimise financial loss.
With a limited time on the project, it was imperative to move at pace and invest effort wisely. Without direct access to users, I relied on surveys to rapidly uncover valuable insights which formed the starting point for my area of focus.
After synthesizing the data, there were several themes that stood out. I discovered a disconnect between the desires of the senior sponsors and the users, with many of the features proposed by the sponsors being perceived of little value for day-to-day operations.
A discovery workshop was conducted with business stakeholders, technical experts and a selection of users in order to prioritise features based on impact and feasibility, explore potential solutions and align on a shared product vision going forward.